

Table S1. Uni- and multivariate analyses for progression-free survival.

CHARACTERISTICS	N	Months	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
			HR (95% CI)	<i>p</i>	HR (95% CI)	<i>P</i>
Treatment Arm						
<i>Doublet CT + bevacizumab</i>	502	9.6	1	<0.001	1	0.001
<i>FOLFOXIRI + bevacizumab</i>	497	11.9	0.74 (0.65-0.84)		0.76 (0.66-0.87)	
Age						
≥70 years	141	10.8	1	0.70	-	
<70 years	858	10.6	0.96 (0.80-1.16)			
ECOG PS						
1-2	131	7.8	1	<0.001	1	<0.001
0	868	11.2	0.57 (0.47-0.68)		0.61 (0.50-0.75)	
Liver-Only Disease						
Yes	276	12.2	1	0.0006	1	0.018
No	721	9.9	1.29 (1.11-1.49)		0.69 (0.51-0.94)	
Missing	2	24.3				
Number of metastatic sites						
1	352	12.3	1	<0.001	1	<0.001
>1	645	9.7	1.44 (1.26-1.66)		1.80 (1.34-2.40)	
Missing	2	24.3				
Resected Primary Tumor						
No	486	10.0	1	0.0005	1	0.032
Yes	513	11.1	0.80 (0.70-0.91)		0.85 (0.74-0.99)	
Gender						
Female	414	10.9	1	0.20	-	
Male	585	10.6	1.09 (0.96-1.24)			
Site of Primary Tumor						
Right	360	10.0	1	0.17	-	
Left	617	11.2	0.91 (0.79-1.04)			
Missing	22	9.4				
RAS/BRAF Mutational Status						
<i>RAS/BRAF wild-type</i>	193	12.3	1		1	
<i>RAS mutated</i>	576	10.3	1.24 (1.04-1.47)	0.0154	1.24 (1.04-1.47)	0.016
<i>BRAF mutated</i>	84	7.4	1.82 (1.40-2.38)	<0.001	1.93 (1.47-2.54)	<0.001
<i>Missing</i>	146	11.6				

N: number; HR: Hazard Ratio; CI: Confidence Interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status.

Table S2. Uni- and multivariate analyses for overall survival.

CHARACTERISTICS	N	Months	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS	
			HR (95% CI)	<i>p</i>	HR (95% CI)	<i>P</i>
Treatment Arm						
<i>Doublet CT + bevacizumab</i>	502	23.0	1	0.016	1	0.13
<i>FOLFOXIRI + bevacizumab</i>	497	26.9	0.84 (0.72-0.97)		0.88 (0.75-1.04)	
Age						
<i>≥70 years</i>	141	23.6	1	0.23	-	
<i><70 years</i>	858	24.8	0.88 (0.72-1.08)			
ECOG PS						
<i>1-2</i>	131	15.2	1	<0.001	1	<0.001
<i>0</i>	868	26.3	0.46 (0.37-0.56)		0.49 (0.39-0.60)	
Liver-Only Disease						
<i>Yes</i>	276	31.4	1	<0.001	1	0.30
<i>No</i>	721	22.7	1.48 (1.25-1.75)		0.83 (0.58-1.18)	
<i>Missing</i>	2	28.4				
Number of metastatic sites						
<i>1</i>	352	30.3	1	<0.001	1	0.0061
<i>>1</i>	645	21.6	1.55 (1.32-1.81)		1.59 (1.14-2.22)	
<i>Missing</i>	2	28.4				
Resected Primary Tumor						
<i>No</i>	486	22.5	1	<0.001	1	0.018
<i>Yes</i>	513	26.6	0.78 (0.67-0.90)		0.82 (0.70-0.97)	
Gender						
<i>Female</i>	414	26.1	1	0.52	-	
<i>Male</i>	585	24.2	1.05 (0.91-1.22)			
Site of Primary Tumor						
<i>Right</i>	360	20.6	1	<0.001	1	0.018
<i>Left</i>	617	26.9	0.72 (0.62-0.84)		0.81 (0.68-0.97)	
<i>Missing</i>	22	21.8				
RAS/BRAF Mutational Status						
<i>RAS/BRAF wild-type</i>	193	35.8	1			
<i>RAS mutated</i>	576	23.7	1.73 (1.41-2.14)	<0.001	1.69 (1.36-2.09)	<0.001
<i>BRAF mutated</i>	84	14.0	3.17 (2.36-4.27)	<0.001	3.03 (2.20-4.16)	<0.001
<i>Missing</i>	146	26.5				

N: number; HR: Hazard Ratio; CI: Confidence Interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status.